ZOLL Heart Failure Management System

 

BMAD Trial Results:
Reduce Readmission and Improve Outcomes with ZOLL HFMS

The Benefits of MicroCor in Ambulatory Decompensated Heart Failure (BMAD) Trial demonstrated the impact of utilizing ZOLL^® Heart Failure Management System* (HFMS) for fluid management following an acute decompensation event.¹

 

Early Pulmonary Fluid Detection and Improved Outcomes

Pulmonary fluid can accumulate days before patients experience noticeable symptoms, and can be an early indicator of a heart failure decompensation event.⁵

 

How ZOLL HFMS Works

ZOLL HFMS is a non-invasive, patch-based device that uses novel radiofrequency technology for early detection of changes in pulmonary fluid levels, an increase in which is an early indicator of heart failure decompensation.

• Radar waves can be used to measure interstitial edema, an early sign of heart failure
• Changes in signal path delay and strength indicate changes in fluid
• Waves are highly modulated by tissue hydration, producing a very sensitive, robust measurement known as Thoracic Fluid Index (TFI)

ZOLL HFMS also records, stores, and transmits additional patient data that can be used to inform care plans, including heart rate, respiration rate, activity, posture, and heart rhythm (ECG).

 

 

Heart Failure on the Rise

Heart failure is one of the largest clinical challenges facing healthcare today, affecting nearly 6 million Americans.⁶ The current U.S. expenditure for heart failure exceeds $30 billion annually, with 60-80 percent related to hospitalization, and these figures are expected to grow in the future.⁷

 

Support for You and Your Patients

From prescription to timely alerts, ZOLL supports every step of the process so that your team can focus on optimizing care and improving outcomes.

ZOLL HFMS may benefit patients who:

• Have had an acute event for volume overload and have been effectively diuresed, are now stable, and will benefit from remote pulmonary fluid management to predictively prevent a recurrent hospitalization
• Have intermittent and/or poorly controlled dyspnea, orthopnea, edema, or other fluid overload-related symptoms
• Require GDMT pharmaceutical titration to control fluid overload

 

*FDA registered name: μCor™ Heart Failure and Arrhythmia Management System; FDA 510(k) #K172510

 

¹Boehmer J, et al. Impact of Heart Failure Management Using Thoracic Fluid Monitoring From a Novel Wearable Sensor: Results of the Benefits of Microcor (μCor™) in Ambulatory Decompensated Heart Failure (BMAD) Trial. Presented as Late Breaking Clinical Trial at the 2023 American College of Cardiology Annual Scientific Session, March 6, 2023.

²Costanzo MR, Ronco C, Abraham WT, et al. Extracorporeal Ultrafiltration for Fluid Overload in Heart Failure: Current Status and Prospects for Further Research. J Am Coll Cardiol. 2017;69(19):2428-2445.

³Fonarow GC, Abraham WT, Albert NM, et al. Factors identified as precipitating hospital admissions for heart failure and clinical outcomes: findings from OPTIMIZE-HF. Arch Intern Med. 2008;168(8):847-854.

⁴Khan MS, Sreenivasan J, Lateef N, et al. Trends in 30- and 90-Day Readmission Rates for Heart Failure. Circ Heart Fail. 2021;14(4):e008335.

⁵Adamson PB. Pathophysiology of the transition from chronic compensated and acute decompensated heart failure: new insights from continuous monitoring devices. Curr Heart Fail Rep. 2009 Dec;6(4):287-92.

⁶Heidenreich PA, Albert NM, Allen LA, et al. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail. 2013;6(3):606-619.

⁷Desai AS, Stevenson LW. Rehospitalization for heart failure: predict or prevent?. Circulation. 2012;126(4):501-506.